
Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval
来源:WSJ发布于 2026-11-16
The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
相关标的:NVO
本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。